On 13 May 2020, a delegation of 8 led by Dai Tao, Deputy Director of the Medical and Health Science and Technology Development Research Center of the National Health Commission; Zheng Ying, Researcher at the Health Policy Research Center of the Chinese Academy of Medical Sciences; and Xi Kebo, Deputy Director of the Science, Technology, Education and International Cooperation Division of the Municipal Health Commission, visited Beike Biotech to inspect the development of health science and technology innovation. Dr. Hu Junyuan, Chairman of Beike Biotech, warmly received the delegation.
At the discussion meeting, Dr. Hu Junyuan, Chairman of Beike Biotech, briefed the delegation on the company's outstanding innovative achievements in the stem cell field. After hearing the briefing and the related views, Director Dai Tao fully recognized Beike Biotech's work in innovative R&D and capability building in frontier biopharmaceutical industries – particularly in the stem cell field. He gained a thorough understanding of the issues faced by enterprises in their innovative development and encouraged Beike Biotech to actively participate in the building of national health science and technology innovation development.
Beike Biotech possesses a top-tier stem cell research team and frontier cell storage and preparation technologies. Its innovative "Comprehensive Cell Bank + Regional Cell Intelligent-Manufacturing Center + Cell Quality Inspection Platform" industrial development model provides an innovative public technology platform and infrastructure for the clinical translation of cell therapy technology, while also laying a data foundation for the future development of AI + biomedicine. During this fight against the pandemic, Beike Biotech also actively participated in tackling technical challenges. In partnership with the Third People's Hospital of Shenzhen (Shenzhen's only designated hospital for receiving COVID-19 patients), the company applied for and was granted approval for the project "Clinical Research on Treating Severe Pneumonia Caused by Coronavirus with Human Umbilical Cord Mesenchymal Stem Cells" (click for details), under the Guangdong Department of Science and Technology's 2020 Guangdong Emergency Special Project on Scientific and Technological Tackling for the Prevention and Control of Novel Coronavirus. At the same time, the clinical research on mesenchymal stem cell therapy for critically ill COVID-19 patients, jointly carried out by Beike Biotech with multiple medical institutions in Yunnan, has produced milestone results, with the article "Human Umbilical Cord Mesenchymal Stem Cells in Combination with Antiviral and Other Methods for the Treatment of Novel Coronavirus Pneumonia" published (click for details), contributing to the fight against the pandemic.
